Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting

Posted on May 21 2010 by Pat Killingsworth | 776 views

Here are parts of a press release Onyx, makers of the new drug, carfilzomib, released last night at 6:00 PM:

Emeryville, CA – May 20, 2010 – Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL. Presentations will highlight data from the carfilzomib development program in patients with relapsed/refractory multiple myeloma and solid tumors. Each presentation will include updated data at the annual meeting that will not be available in the online abstracts at www.asco.org.

“We are further encouraged by the growing body of evidence that supports carfilzomib’s potential as a new treatment option for patients with multiple myeloma,” said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx. “We look forward to sharing final data from our Phase 2b 003-A1 pivotal trial that we anticipate will form the basis of an initial New Drug Application (NDA) filing for cafilzomib by year end.”

Onyx researchers will be making five important data presentations at ASCO.  These include Results of an Ongoing Open-Label, Phase 2 Study of Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (MM) and a patient quality of life related study, Neurotoxic and Peripheral Neuropathic Effects in Preclinical and Clinical Studies of Carfilzomib, a Novel Proteasome Inhibitor (PI).

I am hoping to conduct a number of interviews with Onyx researchers at ASCO. Tomorrow I am posting an editorial about my impressions, from a multiple myeloma patient’s perspective, about the emergence of carfilzomib.  Feel good and keep smiling!  Pat

2 Comments For This Post

  1. Rebecca Weber Says:

    I loved the article. Thank you. And I wish you success at the ASCO. I am so looking forward to reading about what's in the pipeline for our lifetime. I like the fact that the drug companies will be able to speak with someone who has myeloma and how your advocacy for us will certainly give them a different perspective about myeloma. I am praying so hard that you will make a difference to the drug companies. Thank you so much Pat! We need you. I just re-read this and thought how demanding I sound. I do not mean to come across this way. I see you as one of the best advocates for myeloma patients. Reading you gives me hope.

    Rebecca

  2. Pat and Pattie Killingsworth Says:

    Dearest Rebecca-
    You aren't being demanding! That's how I feel… Like I can't waste a minute! Good thing my therapy is holding. Every advancement, every good check-up means the potential for more time. I could talk and write about this subject for hours. A chapter in my book is dedicated to the concept of time and how it changes after a cancer diagnosis. But it only scratches the surface. One of my priorities: Help get the drug companies and oncology docs to focus more on patient quality of life. If we are living longer, is anyone paying attention to what the long term effect of all of these drugs is on our bodies? Pat

Leave a Reply


Follow On Twitter!

Follow HelpWithMyeloma on Twitter

Archives